Curemark

Curemark is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neuro-developmental and neurodegenerative disorders, with a strong focus on Autism Spectrum Disorder treatment. Founded in 2004 and headquartered in Rye, US, Curemark specializes in developing therapies targeting neuro-developmental disorders. The company has raised USD 20. 00 mn in funding from Frist Capital on July 14, 2015, focusing its efforts on the commercialization of its lead product, CM-AT.

Joan Fallon serves as the CEO, bringing her extensive experience from prior ventures to drive the company’s growth. Curemark is focused on innovative therapies for neuro-developmental and neurodegenerative disorders. Their lead product, CM-AT, is an orally-delivered enzyme replacement therapy designed specifically for treating Autism Spectrum Disorder by addressing underlying enzyme deficiencies. The product has successfully completed two Phase III trials and is prepared for commercialization for pediatric patients diagnosed with Autism as young as three years old.

Additionally, Curemark has a pipeline that includes therapies for ALS, ADHD, and Parkinson’s Disease, targeting markets in North America, Europe, and Asia. Curemark's revenue model is centered on the direct sales of its proprietary therapies, particularly CM-AT. Once launched, sales will primarily involve B2B transactions with healthcare providers and institutions, with a pricing strategy aligned to industry standards for specialized enzyme replacement therapies. Plans will include partnerships with pharmaceutical distributors and collaborations with insurance providers to facilitate patient access and reimbursement pathways post-approval.

Curemark plans to utilize the USD 20. 00 mn raised in July 2015 to advance the commercialization of CM-AT and develop additional products within its pipeline. The company aims to launch CM-AT targeted at pediatric markets in North America, Europe, and Asia. Further, Curemark is focused on expanding its presence in these regions to enhance patient access to its therapies.